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Clinical relevance of positive patch test reactions
to the 26 EU-labelled fragrances
ELEONOOR J. VAN OOSTEN, MARIE-LOUISE A. SCHUTTELAAR AND PIETER JAN COENRAADS
Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
Background: Fragrance mix I (FM I) and fragrance mix II (FM II) in the European baseline series are
used as screening tools for fragrance contact allergy. In 2005 the European Union (EU) required labelling
of 26 fragrances when present in cosmetic products. INCI nomenclature is obligatory for such labelling.
Objectives: To describe frequencies of contact allergy to these 26 fragrance substances, and to evaluate
clinical relevance of these positive reactions.
Methods: Three hundred and twenty patients with eczema suspected of being contact allergy to fragrances
or cosmetics were patch tested with the EU-declared fragrance chemicals, FM I and FM II.
Results: There were 76 positive reactions in 33 patients. Most reactions were to hexyl cinnamal and
hydroxyisohexyl 3-cyclohexene carboxaldehyde in 3.1%, followed by Evernia furfuracea (2.5%) and
cinnamyl alcohol (2.5%). Twelve reactions to FM I and II were not confirmed by separate ingredients.
Clinical relevance of positive reactions to fragrances was certain in 20/33 (61%).
Conclusions: 10.3% of the patients had positive patch tests in the EU-list. Hydroxyisohexyl
3-cyclohexene carboxaldehyde, a component of FM II, was the most frequent allergen, followed by
Evernia furfuracea. Since Evernia furfuracea is not part of FM I or FM II, relevant reactions can be
missed when only the European baseline series is used.
Key words: contact allergy; European Union; fragrances; fragrance mix; patch testing. © John Wiley
& Sons A/S, 2009.
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Introduction
Contact allergy to fragrances is a common cause
of contact dermatitis. In modern society people are
exposed to fragrances and other cosmetic ingredi-
ents on a daily basis. Even so-called unperfumed
products may still contain fragrance ingredients.
Furthermore, fragrance materials are also present in
household products and industrial materials (1).
According to some studies, contact allergy to
fragrances may affect up to at least 1% of the general
adult population (2–5). In patients with eczema the
frequency of contact allergy to fragrances is higher,
probably between 6% and 14% (6). After nickel
sulphate, fragrances seem to be the most common
contact allergens.
The diagnosis fragrance allergy can be made by
patch testing with the European baseline fragrance
mix I (FM I). FM I consists of eight differ-
ent fragrances: amyl cinnamal, cinnamyl alco-
hol, cinnamal, eugenol, geraniol, hydroxycitronel-
lal, isoeugenol and Evernia prunastri. It is assumed
that the FM I detects 70–80% of the fragrance
allergic patients (2, 7–9). A second fragrance mix
(FM II), containing six fragrances: citral, citronellol,
coumarin, farnesol, hexyl cinnamal and hydroxyiso-
hexyl 3-cyclohexene carboxaldehyde was developed
to detect patients with fragrance allergy who would
have been missed with FM I alone (10). The FM
II has shown to detect additional patients (about
one-third) sensitive to fragrances missed by FM
I (8, 11).
26 fragrance chemical (INCI nomenclature;
Table 1) contact allergens listed by the relevant
scientific advisory committee of the European Com-
mission have, since (7) March 2005, been indicated
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Table 1. Positive and irritant reactions to the individual fragrances of the EU-list (n = 320)
Fragrance chemical (INCI) Test concentration FM I/ FM II n pos % pos + ++ +++ n IR % IR
1 Hydroxyisohexyl 3-cyclohexene
carboxaldehyde 2% FM II 10 3.1 9 1 — 2 0.6
2 Cinnamyl alcohol 2% FM I 8 2.5 5 3 — 1 0.3
Evernia furfuraceaa 2% — 8 2.5 7 1 — 4 1.3
3 Hydroxycitronellal 2% FM I 7 2.2 5 2 — 1 0.3
4 Evernia prunastri 2% FM I 6 1.9 4 2 — 2 0.6
5 Cinnamal 1% FM I 5 1.6 2 3 — 1 0.3
6 Eugenol 2% FM I 4 1.3 3 1 — 1 0.3
Isoeugenol 2% FM I 4 1.3 2 1 1 1 0.3
7 Farnesol 5% FM II 3 0.9 3 — — 3 0.9
8 Amylcinnamyl alcohol 1% — 2 0.6 2 — — 1 0.3
Citral 2% FM II 2 0.6 2 — — 0 —
Coumarin 5% FM II 2 0.6 2 — — 0 —
Geraniol 2% FM I 2 0.6 2 — — 2 0.6
Hexyl cinnamal 5% FM II 2 0.6 2 — — 1 0.3
Butylphenyl methylpropional 1% — 2 0.6 2 — — 0 —
Linalool 10% — 2 0.6 2 — — 0 —
Alpha-isomethyl ionone 5% — 2 0.6 2 — — 1 0.3
9 Benzyl alcohol 1% — 1 0.3 1 — — 1 0.3
Benzyl salicylate 2% — 1 0.3 1 — — 1 0.3
Citronellol 2% FM II 1 0.3 1 — — 0 —
Methyl-2-octynoate 0.5% — 1 0.3 1 — — 2 0.6
10 Amyl cinnamal 2% FM I 0 — — — — 2 0.6
Anisyl alcohol 5% — 0 — — — — 2 0.6
Benzyl benzoate 5% — 0 — — — — 0 —
Benzyl cinnamate 5% — 0 — — — — 0 —
d-Limonene 2% — 0 — — — — 0 —
ain di-ethyl phthalate. FM I, fragrance mix I; FM II, fragrance mix II; n pos, hydroxyisohexyl number of patients with positive patch test
reactions; % pos, percentage of patients with positive patch test reaction; reaction pattern of positive patch test reactions (+, ++, +++);
n IR, number of patients with irritant patch test reaction; % IR, percentage of patients with irritant patch test reaction.
on cosmetic ingredient labels if present at 10 parts
per million (ppm) or more in leave on, or 100 ppm
or more in rinse off cosmetic products. From
October 2005 detergents and similar products have
also been labelled. All the fragrance ingredients of
FM I and FM II are included in the EU-list.
The current study investigated the frequencies of
contact allergy to these 26 fragrances in patients
with eczematous skin disease, and to evaluate the
clinical relevance of the positive patch test reactions.
Additionally, we evaluated if patch testing with the
full EU-list of declared fragrances had an additional
benefit in the diagnosis of contact allergy.
Materials and Methods
From April 2005 to June 2007 a total of 320 patients
were interviewed and patch tested. The patients were
recruited from the outpatient department of Derma-
tology at the University Medical Center in Gronin-
gen, the Netherlands. Selection of the patients was
made according to the following criteria: patients
with eczema suspected of a contact allergy to fra-
grances or cosmetics and eczema localized on the
face, neck, hands, axillae, genital area, or general-
ized eczema.
All 320 patients were tested with the series of
26 EU fragrance ingredients that are labelled. Addi-
tionally, the European baseline series (TRUE® test,
Mekos laboratories, Denmark), which includes FM
I, was tested in 295 patients, and the FM II (Her-
mal/Trolab, Reinbek, Germany) was tested in 227
patients. The fragrance compounds were obtained
from Hermal/Trolab and from other international
suppliers (International Flavors & Fragrances, USA;
Robertet, France; Givaudan, Switzerland, Milen-
nium Speciality Chemicals Inc., USA; Bedoukian
Research Inc., USA; Rhodia, France; Symrise, Ger-
many and Firmenich, Switzerland). All fragrances
were dissolved in petrolatum, except for Evernia
furfuracea which was dissolved in di-ethyl phtha-
late (Table 1). Patch tests were performed and read
according to the guidelines of the International Con-
tact Dermatitis Research Group (ICDRG) (12). The
patches were applied for 2D. Final reading was done
on D3. (7, 13). Reading of doubtful reactions was
done up to D7 after the application of the patch
test material. The relevance of the positive reactions
(1+ through 3+) was determined and categorized as
certain, probable, possible or not relevant. Contact
allergy was defined as clinically relevant accord-
ing to the following criteria: (i) certain exposure to
the sensitizer and (ii) the patients dermatitis can be
explained by the exposure (8, 11, 14, 15).
A standardized history (including sex, age, occu-
pation, exposures) together with the primary site of
dermatitis were carefully noted. At the same time
the patients were interviewed about their history of
adverse reactions to fragrances or cosmetic products.
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Each patient was assigned to one of four categories
according to their history of fragrance intolerance.
The first category was ‘Certain’ ; the patient had
reacted with an itching dermatitis to at least one
fine perfume or aftershave and had reacted to other
scented products. The second category is ‘Proba-
ble’ ; the patient had reacted to one or more scented
products (e.g. deodorant) but a specific perfume had
not been identified as the cause of a clinical reaction.
The third category was ‘Questionable’ ; the patient
had reacted to various cosmetics with or without fra-
grances. Materials other than fragrance constituents
could have been the cause of a reaction in this cat-
egory of patients. And the last category is ‘None’ ;
the patient had never reacted to a scented material.
Results
Frequencies of sensitization
A total of 320 patients was patch tested with a mean
age of 39 years (range: 2–85 years). There were
231 women tested (72.2%) and 89 men (27.8%).
Most of these patients had eczema of the face or
hands (Table 3). We found a total of 76 positive
reactions in 33 patients (19 women, 14 men), which
means that 10.3% of all patients tested (women
8.2%, 19 out of 231; men 15.7%, 14 out of 89)
had one or more positive reactions to fragrance
ingredients. Of the 76 positive reactions, 51 (67.1%)
were found in women and 25 (32.9%) in men. Most
positive reactions were 1+ (61; 80.3%). Of these
1+ reactions 38 were found in the group of women
(62.3%) and 23 in the group of men (37.7%). There
were 14 (18.4%) ++ reactions of which 12 were
found in the group of women (85.7%) and 2 in the
group of men (14.3%). And there was only 1 +++
reaction (1.3%; with a woman).
The results of patch testing to the individual fra-
grances are listed in Table 1. Most positive reac-
tions were seen to hydroxyisohexyl 3-cyclohexene
carboxaldehyde with 3.1%, Evernia furfuracea and
cinnamyl alcohol (2.5%), hydroxycitronellal (2.2%),
Evernia prunastri (1.9%), cinnamal (1.6%), eugenol
and isoeugenol (1.3%). We did not find any pos-
itive reactions to amyl cinnamal, anisyl alco-
hol, benzyl benzoate, benzyl cinnamate, and d-
limonene. The total number of irritant reactions
was 30 (21 in women, 70%; and 9 in men, 30%).
These irritant reactions were found in 16 (5%)
patients (12 women, 5.2% of the women; 4 men,
4.5% of the men). Most irritant reactions were
observed to Evernia furfuracea with a frequency
of 1.3% (4 out of 320 patients), and farnesol
with a frequency of 0.9% (3 out of 320). There
were 12 doubtful reactions at D3. At D7 after
start of the test, only one of these reactions was










Face 79 24.7% 15.6
Hands 78 24.3% 25.0
Periorbital 52 16.3% 6.3
Neck 25 7.7% 9.4
Trunk 21 6.7% 6.3
Generalized 16 5.0% 12.5
Arms 14 4.3% 9.4
Armpits 11 3.3% 9.4
Scalp 11 3.3% 0
Feet 7 2.3% 0
Legs 6 2.0% 6.3
Number of patients tested (n); Primary localization of eczema of
patients with a positive reaction to one or more fragrances of the
EU-list (% Positive reactions EU-list).
positive (hydroxycitronellal), while the rest was
negative.
The primary site of the eczema of the patients
in this study was in most cases the face, hands, or
periorbital, respectively, 24.7%, 24.3%, and 16.3%
(Table 2). The highest percentage of positive patch
test reactions was found among patients with a pri-
mary location of the eczema of the hands (25.0%),
followed by eczema of the face (15.6%).
Discrepancies between FM I, FM II and the 26
fragrance compounds
The FM I was patch tested in 295 patients (Table 3).
We found a frequency of positive reactions to the
FM I of 5.8% (17 out of 295 patients). A total of
11 patients (3.7%) showed one ore more positive
reactions to the EU-list and also to the FM I. Twenty
patients (6.8%) did react to one or more ingredients
of the EU-list but did not show a positive reaction to
the FM I, and six patients (2.0%) did have a positive
reaction to the FM I but not to a ingredient of the
EU-list.
In 227 patients the FM II was patch tested
(Table 3). We found a frequency of sensitization to
the FM II of 9.3% (21 out of 227 patients). A total
of 14 patients (6.2%) had positive reactions to one
or more ingredients of the EU-list as well as to the
FM II. Twelve patients (5.3%) appeared to have at
least one positive reaction to the EU-list but no
positive reaction to the FM II, and seven patients
(3.1%) did have a positive reaction to the FM II but
not to one of the ingredients of the EU-list.
When the FM I as well as the FM II were patch
tested (Table 2) it appeared that 17 patients (7.5%)
had one or more positive reactions to the ingredients
of the EU-list and also to the FM I and/or the FM II.
A total of 9 (4.0%) patients showed a positive
reaction to the EU-list but not to the FM I and/or
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Table 3. Reactions to fragrances of the EU-list and Treemoss in relation to reactions to FM I and FM II
FM I FM II FM I and/or FM II
Positive Negative Positive Negative Positive Negative
Total number, n 295 227 228
EU-list Positive 11 20 14 12 17 9
Negative 6 258 7 194 12 190
Total number, n 295 227
Evernia furfuracea Positive 5 2 3 3
Negative 12 276 18 203
Fragrance mix I (FM I); Fragrance mix II (FM II); Both FM I and II are patch tested (FM I and/or FM II); Total number of patients tested
(n), Number of patients with positive patch test reactions (Positive); number of patients with no positive patch test reactions (Negative).
FM II, and 12 patients (5.3%) did have a positive
reaction to the FM I and/or FM II but not to an
ingredient of the EU-list.
Table 3 also shows the percentages of positive
and negative reactions to Evernia furfuracea as a
single ingredient compared to the reactions to the
FM I an FM II. A total of five patients (1.7%) had a
positive patch test reaction to Evernia furfuracea as
well as to FM I, and three patients (1.3%) to Evernia
furfuracea and FM II. A total of two patients (0.7%)
showed a positive reaction to Evernia furfuracea but
not to the FM I and three patients (1.3%) had a
positive reaction to Evernia furfuracea but not to
FM II.
Clinical relevance
In 20 out of 33 (60.6%) patients with one or
more positive patch test reactions a certain clinical
relevance of the positive reactions was established,
12.1% (4 out of 33) of the reactions was judged
as probably clinically relevant, 21.2% (7 out of 33)
possibly and in only two patients (6.1%) the positive
reactions were unlikely or not clinically relevant.
History of adverse reactions
A total of 247 patients were interviewed about
their history of adverse reactions to fragrances or
cosmetic products. The outcome of this interview is
shown in Table 4. Most patients (57.1%) could not
recall an adverse reaction to fragrances or cosmetic
products, 19.0% of the patients did have a certain
history of adverse reactions. Of these patients with a
certain adverse reaction to fragrances in their history
46.4% showed also a positive patch test reaction.
Nine (32.1%) patients showed a positive patch test
reaction but never had reported an adverse reaction
to fragrances or cosmetic products.
Discussion
The aims of this study were to describe the fre-
quency of contact allergy to the fragrances of the
Table 4. History of adverse reactions to fragrances or cosmetic













Certain 19.0 (47) 46.6 (13) 27.7
Probable 13.0 (32) 3.6 (1) 3.1
Questionable 10.9 (27) 17.9 (5) 18.5
None 57.1 (141) 32.1 (9) 6.4
Number of patients (n), Number of patients tested (Total
number, n).
EU-list, to evaluate the clinical relevance of the pos-
itive patch test reactions and to investigate if testing
with the EU-list has an additional benefit in the diag-
nostic patch test procedure. The major outcomes of
this study are that we found a high frequency of con-
tact allergy to fragrances of the EU-list of 10.3%,
with most positive reactions to hydroxyisohexyl 3-
cyclohexene carboxaldehyde, cinnamyl alcohol and
surprisingly Evernia furfuracea. The clinical rele-
vance of these positive reactions was 61%. If only
FM I and FM II were patch tested, 4% of all patients
tested with a contact allergy to fragrances would be
missed.
Previous studies on patch testing with FM I and
FM II as a screening tool for contact allergy to
fragrances have reported a frequency of 6.5% of
the patients reacted to FM I and 2.9–4.6% of the
patients reacted to FM II (8, 11, 16, 17). We found
a frequency of sensitization to the list of 26 fra-
grances of 10.3%. Interestingly, we found a differ-
ence in frequency of sensitization between men and
women (15.7% versus 8.2%), while in the literature
it has been described that in eczema patients, the
male:female ratio of FM I allergy is usually 1:2 (18,
19). A more equal distribution between males and
females is seen in the general population, especially
in the younger age groups (20).
We showed most positive patch test reactions
to hydroxyisohexyl 3-cyclohexene carboxaldehyde
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with a frequency of 3.1%. Hydroxyisohexyl 3-
cyclohexene carboxaldehyde is not part of the FM
I. Several recent studies have reported that hydrox-
yisohexyl 3-cyclohexene carboxaldehyde is one of
the most frequent sensitizers in the past years, giv-
ing positive reactions in 1–2.9% of patch tested
patients (3, 10, 11, 21–23). Results on patch test-
ing the 26 fragrances of the EU-list have also been
published by Schnuch et al. in 2007 (10). They
showed a frequency of sensitization to hydroxy-
isohexyl 3-cyclohexene carboxaldehyde of 2.3%.
In our study we found an even higher percentage
of 3.1% positive patch test reactions to hydroxy-
isohexyl 3-cyclohexene carboxaldehyde. Striking is
the high percentage (2.5%) of patients with posi-
tive patch test reactions to Evernia furfuracea in
our study. Schnuch and co-workers were the first
who tested Evernia furfuracea in a larger unse-
lected population (10). They found a similar per-
centage of 2.4%. In their study it was even the
most frequent allergen followed by hydroxyisohexyl
3-cyclohexene carboxaldehyde, although they used
unselected patients. These comparable results seem
to show that the high percentage of positive reac-
tions to Evernia furfuracea we found may not be
due to the fact that a different vehicle was used.
Evernia furfuracea is not part of FM I or FM II and
is therefore not used as a screening agent for contact
allergy to fragrances. Our study showed that 2 out of
295 (0.7%) tested had a positive reaction to Evernia
furfuracea but were missed by testing only with the
FM I and 3 out of 227 (1.3%) of the patients who
were positive to Evernia furfuracea were missed by
testing only FM II. Perhaps Evernia furfuracea is
used in a lot of perfumed products and therefore the
high frequency of contact allergy to Evernia fur-
furacea can be explained. Cinnamyl alcohol seems
to be converted in the skin to the chemically related
cinnamal. Cinnamal is known as a strong allergen
and has been one of the highest ranking fragrance
allergen for many years, but recently there is a
striking reduction in the frequency of sensitivity to
cinnamal (with 18% yearly) and also cinnamyl alco-
hol. They are nowadays considered as uncommon
allergens (18, 24, 25). However, our study shows
that sensitization to cinnamal as well as cinnamyl
alcohol is still common in our eczema patients with
frequencies of 1.6% versus 2.5%. Previous studies
reported for isoeugenol a sensitization frequency of
1.7% and 1.1%, which is comparable to the 1.3% in
our study (10, 26). Eugenol was classified as a less
important allergen, although frequently used, by a
recent study of Schnuch et al. (10). They found a
sensitization frequency of only 0.4% while our study
showed that eugenol was one of the common aller-
gens with a frequency of 1.3%. This difference in
positive reactions may be explained by the higher
concentration of 2% used by us.
Interestingly, the single ingredients of FM I and
II and Evernia furfuracea are the highest ranking
allergens of the total of 26 fragrance ingredients
tested except for citronellol and amyl cinnamal.
Citronellol is part of FM II and previous studies
showed frequencies of sensitivity of 0.2–0.5% (10,
11, 22). In this study we found a comparable
frequency of 0.3%. We found no positive patch
test reactions to amyl cinnamal which is part of
FM I. A previous study of Schnuch et al. showed
also a frequency of positive patch test reactions of
only 0.1%, which suggests that amyl cinnamal is
not a frequent sensitizer these days (10). Also the
other fragrance ingredients to which we found no
positive patch test reactions (anisyl alcohol, benzyl
benzoate, benzyl cinnamate, and d-limonene) can
be regarded as uncommon allergens. D-limonene
and linalool were used unoxidized. Different studies
have now proved that both d-limonene and linalool
as pure compounds seldom cause positive patch test
reactions. However, their oxidation products have
been shown to cause contact allergy (27–35). There
may have been a certain degree of oxidation during
the storage of our patch test preparations.
In this study we found that if the FM I is tested
alone, 20 patients with a contact allergy to one ore
more fragrance ingredients will be missed. If the
FM II is tested, 14 patients will be missed. If FM I
and II are tested, nine patients with a contact allergy
fragrances will still be missed.
We showed that FM I and II, when tested together,
are important as a screening test for contact allergy
to fragrances. In this study we found that in 60.6%
of the patients with positive patch test reactions
the clinical relevance was judged as certain. As
far as we know, this is the first study where
clinical relevance of positive patch test reactions
was evaluated in this way. It is assumed that the
percentage of clinically relevant reactions in patients
suspected of a contact allergy for fragrances lies
between the 50% and 65% (1, 2). Still 21.2 % of the
sensitized patients had positive patch test reactions
that were possibly clinically relevant and 6.1%
of the patients had no clinically relevant contact
sensitization. Although there are a lot of studies that
report the frequency of positive patch test reactions
to fragrances, the assessments of the relevance of
these reactions were not always clear, or different
methods were used (1, 6, 11, 36, 37).
Of all patients questioned about their history of
adverse reactions to fragrances or other cosmetic
products, most people (57.1%) were unaware of any
adverse reaction. However 19% of the patients inter-
viewed did have a certain adverse reaction in their
history. De Groot et al. (1) found that 12% of the
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general population reported an adverse reaction to
cosmetics or toiletries in the past 5 years. Of these
12%, another 35% of these patients (4.3% of the
total population) attributed this adverse reaction to
products used for their odour, such as deodorants,
aftershaves, and perfumes. Of our patients with a
history of adverse reactions 27.7% also had one or
more positive patch test reactions and were recog-
nized as sensitized to fragrances. This means that the
rest of this group (72.3%) may have had an adverse
reaction to other ingredients of scented products like
preservatives.
In conclusion, we found a high frequency of con-
tact allergy to fragrances by using all the 26 fra-
grance allergens labelled on products in the EU.
The most important sensitizers are ingredients of
FM I, FM II and also the single ingredient Ever-
nia furfuracea. Compared to the complete EU-list
screening for patients with a contact allergy for fra-
grances with the FM I and FM II some patients will
be missed. Therefore, it seems necessary to include
Evernia furfuracea in one of these fragrance mixes.
Testing with Evernia furfuracea in to FM I and II
indentifies fragrance allergy in an additional 4% of
the population that has been tested. Interesting is the
difference we found between the clinical relevance
of positive reactions and the patients’ history of
adverse reactions to fragrances: the patients’ histo-
ries indicated fewer adverse reactions to fragrances
than the number of reactions with clinical relevance
according to the doctor’s assessment.
If a patient has a positive patch test to one of
the fragrance mixes, it is unknown which single
ingredient caused this positive reaction. Therefore,
it is helpful to test with a list of single ingredients
like the EU-list. Our study confirmed the findings of
Schnuch et al. (10) who showed very low frequen-
cies of sensitization to some fragrance compounds
which indicates that these compounds may not be
common allergens. These findings suggest that in
the future the EU-list may need revision. However,
only two studies have been published thus far on
patch testing the 26 single ingredients of the com-
plete EU-list. It is highly recommended that more
studies in different European populations should be
performed, as there might be differences in contact
allergy to fragrances in different countries.
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